We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance



Results: 1-10 of 46

CETA and Canadian IP law: Possible changes ahead?
  • Gowling WLG
  • Canada, European Union
  • March 3 2016

In 2013, an agreement in principle was reached between Canada and the European Union - theCanada-European Union Comprehensive Economic and Trade


Novopharm Limited v. Eli Lilly and Company (2010 FC 915)
  • Gowling WLG
  • Canada
  • October 27 2010

An impeachment action was brought by Novopharm in respect of a patent for STRATTERA alleging obviousness, anticipation, utility and improper selection


Pfizer v Ratiopharm, appeal of decision on invalidity, Amlodipine Besylate, July 29, 2010
  • Gowling WLG
  • Canada
  • August 26 2010

In the Federal Court, Pfizer's patent for amlodipine besylate was held invalid on numerous grounds, including obviousness


Apotex v. Pfizer, motion to strike part of a defence pertaining to res judicata, sildenafil citrate, June 11, 2010
  • Gowling WLG
  • Canada
  • July 16 2010

Apotex applied to impeach Pfizer's patent for Viagra and Pfizer defended alleging, in part, res judicata


Apotex v Syntex and Roche, dismissal of appeal concerning section 8 of PMNOC Regulations, naproxen, June 10, 2010
  • Gowling WLG
  • Canada
  • July 16 2010

Apotex had sued Roche for damages pursuant to s. 8 of the PMNOC Regulations


Time for change? Potential impact of Canada’s trade negotiations on pharma patents
  • Gowling WLG
  • Canada
  • April 22 2013

Bringing a new drug to market is a costly and time-consuming endeavour. It is a process inherent with the risk of failure. In recognition of this


Methods of medical treatment claims issues in Canada, US and Europe
  • Gowling WLG
  • Canada, European Union, USA
  • November 30 2012

In this presentation, Scott Foster and Konrad Sechley address methods of medical treatment claims issues in Canada, US and Europe


Apotex v Lundbeck, motion to strike pleadings and for security for costs, escitalopram, August 5, 2010
  • Gowling WLG
  • Canada
  • September 21 2010

In earlier PMNOC proceedings, Lundbeck successfully obtained an order prohibiting the Minister from issuing a Notice of Compliance to Apotex in respect of its escitalopram product


Apotex v. Janssen-Ortho, motion to vary order of Federal Court of Appeal, levofloxacin, August 20, 2010
  • Gowling WLG
  • Canada
  • September 21 2010

Apotex filed a Notice of Allegation alleging that a particular patent licensed by Janssen-Ortho was invalid and not infringed


Eli Lilly v Novopharm, motion for reconsideration of judgment of Federal Court of Appeal (“FCA”), olanzapine, September 7, 2010
  • Gowling WLG
  • Canada
  • September 21 2010

Novopharm moved for reconsideration of the FCA's judgment allowing Lilly's appeal of a Federal Court decision that impeached Lilly's patent